Authors
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, Markus M Lerch, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Giessen-Jung, Markus Moehler, Andreas Jagenburg, Thomas Kirchner, Andreas Jung, Volker Heinemann
Publication date
2016/10/1
Journal
The Lancet Oncology
Volume
17
Issue
10
Pages
1426-1434
Publisher
Elsevier
Description
Background
FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer. The same study also reported an exploratory analysis of a subgroup of patients with tumours that were wild-type at other RAS genes (KRAS and NRAS exons 2–4). We report here efficacy results for the FIRE-3 final RAS (KRAS/NRAS, exons 2–4) wild-type subgroup. Moreover, new metrics of tumour dynamics were explored during a centralised radiological review to investigate how FOLFIRI plus cetuximab conferred overall survival benefit in the absence of differences in investigator-assessed objective responses and progression-free survival.
Methods
FIRE-3 was a randomised phase 3 trial comparing FOLFIRI plus cetuximab with FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS exon …
Scholar articles
S Stintzing, DP Modest, L Rossius, MM Lerch… - The Lancet Oncology, 2016
S Stintzing, DP Modest, L Rossius - LANCET ONCOLOGY, 2016